AstraZeneca stock price forecast: Bullish technicals prevail as AZN jumps 3.40%

Traders Union
All News
Financial News
AstraZeneca jumps 3.40% to $14,646 today

Highlights

AstraZeneca posted strong Q4 2025 results with revenue of $15.5 billion and annual after-tax profit reaching $10.23 billion, supporting a raised dividend to $3.20 per share for 2025.
The company announced a $15 billion investment to localize production in China and emphasized robust performance in its cancer medicines and late-stage pipeline.
AstraZeneca trades at $14,646.00, well above key moving averages, with immediate resistance near $15,000 and strong bullish momentum, though several oscillators signal overbought conditions.

Upbeat earnings and dividend outlook drive profit optimism and expansion

AstraZeneca reported strong full-year and fourth-quarter 2025 results, with revenue hitting $15.5 billion in Q4 and annual after-tax profit rising to $10.23 billion. The company raised its dividend to $3.20 per share for 2025 and announced plans to increase it further in 2026, while reaffirming a positive growth outlook. AstraZeneca also revealed a $15 billion investment to localize production in China and highlighted ongoing strength in its cancer medicines and a busy late-stage pipeline.

Momentum strength as resistance nears and overbought signals intensify

The asset shows strong technical momentum, supported by its price being well above MA-20, MA-50, and MA-200. Closest dynamic support is at the Ichimoku Kijun ($13,839.00), while immediate resistance is near $15,000. Momentum indicators such as MACD and ADX remain bullish, but oscillators like Stochastic RSI and Bull/Bear Power signal overbought conditions. RSI and CCI are also in buy or overbought territory, and the Awesome Oscillator continues to align with the positive trend.

Upside potential balanced by risk of correction on weakening demand

Over the coming week, the short-term forecast range is $14,300.00 to $15,200.00, reflecting typical volatility for a blue-chip stock this size. The probability of a further price increase remains high, but if buyers lose momentum, a move below $14,300.00 could spark a correction toward mid-term supports. A push above $15,200.00 would open the door to further upside if buyers remain in control, while consolidation between these levels is the baseline scenario.

Anton Kharitonov, expert at Traders Union, sees AstraZeneca maintaining upward momentum both technically and fundamentally. He notes strong support from bullish indicators, solid earnings, and an enhanced dividend outlook, but warns that overbought signals and potential for correction cannot be ignored. The analyst believes price may stay range-bound between $14,300.00 and $15,200.00 unless buyers drive a clear breakout. "Caution is warranted at these levels — I will only turn constructive if price holds above $15,200.00 with sustained momentum."

Previously it was reported that AstraZeneca PLC is maintaining a bullish trajectory, trading above its key moving averages with strong upward momentum and robust investor sentiment fueled by positive earnings and guidance. However, while momentum indicators such as ADX and MACD remain constructive, mixed overbought signals from Stoch RSI and BBP, alongside resistance near the psychological GBX 14,300 level, highlight elevated short-term risk and potential for volatility as the stock approaches new highs.

Source of Data: AZN Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.